DataOps can provide a Data Cure for healthcare organizations
BioSpectrum Asia|May 2020
Data is of limited value to a healthcare provider if there is no understanding of its nature or potential application.
Charlie Farah
DataOps can provide a Data Cure for healthcare organizations

Data must be analyzed regularly to uncover new insights and gaps. When access is made easier in a governed approach, individuals gain greater knowledge about the available information and how best to use it, helping to build their data literacy skills.Healthcare organizations must bring together the teams working and using data through the adoption of modern technologies. This is how DataOps was born, to fill in the gap.

Data is the lifeblood of every hospital and healthcare organization. Without it, doctors can’t access updated patient records for proper treatment; billing departments are unable to correctly process insurance claims; and research teams are limited in their ability to uncover new findings. Today there are issues with both data availability and access to the right information, for all users in a governed HIPAA compliant structure, that keeps healthcare organizations from effectively scaling the use of data to impact lives.

Data analytics is often discussed as a key element because of its potential to uncover insights that improve operations while also increasing care quality and efficiency. In today’s world of tight budgets and rising costs, its essential that organizations maximize staff time allocated to care and minimize costs. However, even if a hospital provides access to all its data, a lack of data literacy – an individual’s knowledge on how to use and analyze data – could limit data’s effectiveness towards improving care and operations.

Healthcare organizations must find a data cure that will address both data challenges: access to and use of information. The emerging methodology known as DataOps addresses both issues.

Denne historien er fra May 2020-utgaven av BioSpectrum Asia.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra May 2020-utgaven av BioSpectrum Asia.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA BIOSPECTRUM ASIASe alt
Korea develops micro-structured artificial lung model using bioprinting technology
BioSpectrum Asia

Korea develops micro-structured artificial lung model using bioprinting technology

A team of Korean researchers has made a breakthrough that will greatly enhance the efficiency of respiratory disease research, garnering attention.

time-read
1 min  |
BioSpectrum Asia Sep 2024
Philips names Ling Liu as Chief Region Leader of Greater China
BioSpectrum Asia

Philips names Ling Liu as Chief Region Leader of Greater China

Royal Philips, a global leader in health technology, has announced the appointment of Ling Liu as the Chief Region Leader of Philips Greater China.

time-read
1 min  |
BioSpectrum Asia Sep 2024
PW Skills launches School of Healthcare to solve India's critical shortage of medical professionals
BioSpectrum Asia

PW Skills launches School of Healthcare to solve India's critical shortage of medical professionals

PW Skills, the upskilling vertical of Physics Wallah (PW) has announced the launch of School of Healthcare across five cities in India, namely, Noida, Indore, Lucknow, Patna and Delhi.

time-read
1 min  |
BioSpectrum Asia Sep 2024
Australian biotech incubator Proto Axiom announces $20 M Series B first close
BioSpectrum Asia

Australian biotech incubator Proto Axiom announces $20 M Series B first close

Proto Axiom, the Australian biomedical technology incubator, has announced a $20 million first close of its targeted $30 million Series B, to bolster Australia's biotechnology sector through increased intellectual property (IP) retention.

time-read
1 min  |
BioSpectrum Asia Sep 2024
Biogen, Beckman Coulter and Fujirebio to develop new tests for tau pathology
BioSpectrum Asia

Biogen, Beckman Coulter and Fujirebio to develop new tests for tau pathology

Biogen Inc., Beckman Coulter, Inc. (both based in the US) and Japan-based Fujirebio have announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialise new tests for tau pathology in Alzheimer’s disease (AD).

time-read
1 min  |
BioSpectrum Asia Sep 2024
Pfizer upgrades pharma production plant in Melbourne
BioSpectrum Asia

Pfizer upgrades pharma production plant in Melbourne

Australia is stepping up to the global fight against antimicrobial resistance, as Pfizer Australia announces a major upgrade to its manufacturing facility in Melbourne, Victoria.

time-read
1 min  |
BioSpectrum Asia Sep 2024
mRNA as novel active ingredient - Plasmid Factory providing the template for tomorrow's vaccines
BioSpectrum Asia

mRNA as novel active ingredient - Plasmid Factory providing the template for tomorrow's vaccines

PlasmidFactory GmbH was founded in 2000 in Bielefeld/Germany with 4 employees. In the meantime, under the founder and managing director Dr. Martin Schleef, the company has become a well-known contract manufacturer (CDMO) for plasmid and minicircle DNA. Today, PlasmidFactory has ~50 highly qualified employees, and has established a GMP manufacturing facility.

time-read
6 mins  |
BioSpectrum Asia Sep 2024
"Our priorities will include identifying and understanding the challenges while engaging regularly with industry leaders to address their concerns"
BioSpectrum Asia

"Our priorities will include identifying and understanding the challenges while engaging regularly with industry leaders to address their concerns"

K Raja Bhanu has been elevated from Executive Director to Director General of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), effective July 1, 2024. Bhanu brings a wealth of experience from his distinguished career in drug control and regulation. He has a proven track record in advancing drug quality, safety, and regulatory compliance. His leadership at the Drug Control Administration (DCA) was marked by significant initiatives that enhanced drug regulation standards and reinforced India's pharmaceutical reputation globally. In his current role, Bhanu is set to drive the expansion of India's pharmaceutical exports, boost global competitiveness, and adeptly navigate the complexities of international regulations, leveraging his extensive expertise to foster industry growth and global prominence. In an interaction with BioSpectrum, he shared his plans on addressing many challenges before the Indian pharma industry to stay compliant with international regulations. Edited excerpts:

time-read
4 mins  |
BioSpectrum Asia Sep 2024
"Australia has long been a global leader in research, yet our biotech sector has not lived up to its full potential"
BioSpectrum Asia

"Australia has long been a global leader in research, yet our biotech sector has not lived up to its full potential"

Australia's first true biotech incubator, Proto Axiom, has secured $20 million in the first close of its $30 million Series B round to strengthen the nation's biotech sector through greater IP retention. Anthony Liveris, CEO of Proto Axio discusses the incubator's selection criteria, identifying the most promising biotech trends for global health, and outlining the key strengths that make Australian biotech globally competitive. Edited excerpts:

time-read
2 mins  |
BioSpectrum Asia Sep 2024
Unleashing Innovative Wound Care Solutions
BioSpectrum Asia

Unleashing Innovative Wound Care Solutions

The incidence of wounds is rising, especially in the Asia-Pacific (APAC) region. In Australia alone, 420,000 individuals are impacted by chronic wounds, leading to direct healthcare costs of AUD $3 billion, representing 2 per cent of the country's total healthcare expenditure. Similarly, data from Singapore between 2000 and 2017 revealed that the incidence of wounds among hospitalised adults was 300 per 100,000 for those over 18 and 800 per 100,000 for those over 50. Let's explore further.

time-read
5 mins  |
BioSpectrum Asia Sep 2024